REG-Arix Bioscience PLC Unaudited NAV and Notice of Financial Results

Arix BioscienceAnnouncement

29/04/2022 10:45

============

   Arix Bioscience PLC (ARIX)
   Unaudited NAV and Notice of Financial Results

   29-Apr-2022 / 10:44 GMT/BST
   Dissemination of a Regulatory Announcement, transmitted by EQS Group.
   The issuer is solely responsible for the content of this announcement.

   ══════════════════════════════════════════════════════════════════════════

                                        

   PRESS RELEASE

                              Arix Bioscience plc

                                        

                 Unaudited NAV and Notice of Financial Results

    

   LONDON, 29 April 2022: Arix Bioscience plc ("Arix" or the "Company") (LSE:
   ARIX),  a  global  venture  capital   company  focused  on  investing   in
   breakthrough biotechnology companies, announces  the unaudited NAV of  the
   Company as follows:

    

                             NAV Breakdown                                
     Date                                                   Total NAV
              Listed   Unlisted Portfolio  Cash     Other             NAV per
             Portfolio                            Interests            share
                                                                          
   31-Dec-21  £63.3m         £54.6m       £134.2m   £3.3m    £255.4m
                                                                       £1.98
                                                                          
   31-Mar-22  £53.5m         £57.2m       £127.8m   £2.8m    £241.3m
                                                                       £1.87

                                        

    

   In line  with  the  reconstituted  Board's  desire  to  improve  corporate
   governance and  transparency,  and  with the  current  balance  of  public
   companies within the  portfolio, Arix  intends to  provide regular  market
   updates on its  unaudited NAV and  is therefore today  also releasing  its
   position as of 31 March 2022.

    

   Arix will announce its results for  the full year ended 31 December  2021,
   on 5  May  2022  utilising  the  FCA's  temporary  relief  from  reporting
   deadlines due to the impact of the Covid-19 pandemic.  The Board does  not
   expect any material changes to the NAV for the year ended 31 December 2021
   on publication of the audited financial results. 

    

   The Company will also  host a virtual analyst  presentation followed by  a
   Q&A session at  12pm GMT  on 5  May. Analysts  and investors  who wish  to
   participate should visit this  1 link to register.

    

   The webcast  of  the  presentation  will  be  available  on  the  Investor
   Relations     section      of      the      Company's      website      at
    2 https://arixbioscience.com/investor-relations/events-presentations

    

   For any details of the webcast or conference call please contact:
     3 arix@powerscourt-group.com

    

    

                                      ENDS 

    

    

   Enquiries

   For more information on Arix, please contact:

    

   Arix Bioscience plc

   +44 (0)20 7290 1050

   ir 4 @arixbioscience.com

    

   Powerscourt Group

   Sarah MacLeod, Ibrahim Khalil

   +44 (0)20 7250 1446

    5 arix@powerscourt-group.com

    

   About Arix Bioscience plc

   Arix Bioscience  plc  is  a  global venture  capital  company  focused  on
   investing in breakthrough biotech  companies around cutting-edge  advances
   in life sciences.

    

   We collaborate  with exceptional  entrepreneurs and  provide the  capital,
   expertise  and  global  networks  to  help  accelerate  their  ideas  into
   important new treatments for patients. As a listed company, we are able to
   bring this exciting  growth phase of  our industry to  a broader range  of
   investors.  6 www.arixbioscience.com

    

    

   ══════════════════════════════════════════════════════════════════════════

   ISIN:           GB00BD045071
   Category Code:  NOR
   TIDM:           ARIX
   LEI Code:       213800OVT3AHQCXNIX43
   OAM Categories: 3.1. Additional regulated information required to be
                   disclosed under the laws of a Member State
   Sequence No.:   158688
   EQS News ID:    1339853


    
   End of Announcement EQS News Service

   ══════════════════════════════════════════════════════════════════════════

    7 fncls.ssp?fn=show_t_gif&application_id=1339853&application_name=news&site_id=reuters9

References

   Visible links
   1. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=ce1216c6fe89e302ceae5d863303575b&application_id=1339853&site_id=reuters9&application_name=news
   2. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=8ac0ff5be99af1223133e76a50bf28dd&application_id=1339853&site_id=reuters9&application_name=news
   3. mailto:arix@powerscourt-group.com
   4. mailto:charlotte@arixbioscience.com
   5. mailto:arix@powerscourt-group.com
   6. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=889c637ce21c3a47a35c39202ebd9825&application_id=1339853&site_id=reuters9&application_name=news


============